• Biogen and Sangamo to develop neurological disease drugs pharmaceutical-technology
    March 03, 2020
    Biogen and Sangamo Therapeutics have signed a global licensing agreement for the development of drugs to treat neurological diseases, including Alzheimer’s and Parkinson’s diseases.
PharmaSources Customer Service